AU2017374458B2 - Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder - Google Patents

Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder Download PDF

Info

Publication number
AU2017374458B2
AU2017374458B2 AU2017374458A AU2017374458A AU2017374458B2 AU 2017374458 B2 AU2017374458 B2 AU 2017374458B2 AU 2017374458 A AU2017374458 A AU 2017374458A AU 2017374458 A AU2017374458 A AU 2017374458A AU 2017374458 B2 AU2017374458 B2 AU 2017374458B2
Authority
AU
Australia
Prior art keywords
bipolar disorder
formula
mania
group
bipolar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017374458A
Other languages
English (en)
Other versions
AU2017374458A1 (en
Inventor
Sei Myoung Han
Yu Jin Shin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SK Biopharmaceuticals Co Ltd
Original Assignee
SK Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SK Biopharmaceuticals Co Ltd filed Critical SK Biopharmaceuticals Co Ltd
Publication of AU2017374458A1 publication Critical patent/AU2017374458A1/en
Application granted granted Critical
Publication of AU2017374458B2 publication Critical patent/AU2017374458B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2017374458A 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder Active AU2017374458B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
KR10-2016-0170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
AU2017374458A1 AU2017374458A1 (en) 2019-07-04
AU2017374458B2 true AU2017374458B2 (en) 2023-03-02

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017374458A Active AU2017374458B2 (en) 2016-12-14 2017-12-14 Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
ES (1) ES3054693T3 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080005437A (ko) * 2005-04-22 2008-01-11 에스케이 주식회사 신경치료용 아졸 화합물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28529A (id) * 1997-08-14 2001-05-31 Hoffmann La Roche Vinileter heterosiklik untuk gangguan neurologi
US6555585B2 (en) 2000-07-21 2003-04-29 Teva Pharmaceutical Industries, Ltd. Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
DE60223506T2 (de) * 2001-02-27 2008-09-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
AU2009348523B2 (en) 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080005437A (ko) * 2005-04-22 2008-01-11 에스케이 주식회사 신경치료용 아졸 화합물

Also Published As

Publication number Publication date
US20190314337A1 (en) 2019-10-17
IL267195B1 (en) 2024-01-01
AU2017374458A1 (en) 2019-07-04
ES3054693T3 (en) 2026-02-05
BR112019011930A2 (pt) 2019-10-29
US11571410B2 (en) 2023-02-07
JP2020502106A (ja) 2020-01-23
WO2018111008A1 (ko) 2018-06-21
CA3046297A1 (en) 2018-06-21
EP3556366B1 (en) 2025-10-22
CL2019001618A1 (es) 2019-08-23
RU2019121913A (ru) 2021-01-15
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
KR102635938B1 (ko) 2024-02-13
MX2019006940A (es) 2019-09-06
ZA201903747B (en) 2021-01-27
RU2019121913A3 (enExample) 2021-04-21
JP7208139B2 (ja) 2023-01-18
KR20190087572A (ko) 2019-07-24
CN110290788A (zh) 2019-09-27
EP3556366A1 (en) 2019-10-23
MY199104A (en) 2023-10-13
IL267195A (enExample) 2019-07-31

Similar Documents

Publication Publication Date Title
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
EP3556366B1 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
AU2018370164B2 (en) Use of carbamate compound for reducing or treating developmental disorders including fragile X syndrome, Angelman syndrome or Rett syndrome
US20200223838A1 (en) Methods of use of phenoxypropylamine compounds to treat depression
AU2017267160B2 (en) Use of carbamate compound for preventing or treating trigeminal neuralgia
AU2018367729B2 (en) Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure
AU2019344261B2 (en) Carbamate compound and use of formulation comprising same in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
JP2022503784A (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
EP3556363B1 (en) Use of carbamate compound for prevention, alleviation or treatment of pruritus
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
RU2796295C2 (ru) Карбаматное соединение и применение включающей его композиции для профилактики, облегчения или лечения острого стрессового расстройства или посттравматического стрессового расстройства
CA3081223C (en) Use of carbamate compound for preventing, alleviating or treating absence seizure or epilepsy showing absence seizure
HK40005640A (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia
HK40005640B (en) Use of carbamate compound for preventing or treating fibromyalgia or functional syndrome associated with fibromyalgia

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)